Correlation Engine 2.0
Clear Search sequence regions

  • anemia (5)
  • cisplatin (3)
  • dog (2)
  • domain- protein (1)
  • drug design (1)
  • erythropoietin (3)
  • female (1)
  • mice (1)
  • PAS (1)
  • phase (1)
  • PHD (4)
  • PHD2 (2)
  • profiles (1)
  • rat (2)
  • Sizes of these terms reflect their relevance to your search.

    The design and discovery of a new series of (5-alkynyl-3-hydroxypicolinoyl)glycine inhibitors of prolyl hydroxylase (PHD) are described. These compounds showed potent in vitro inhibitory activity toward PHD2 in a fluorescence polarization-based assay. Remarkably, oral administration of 17, with an IC50 of 64.2 nM toward PHD2, was found to stabilize HIF-α, elevate erythropoietin (EPO), and alleviate anemia in a cisplatin-induced anemia mouse model with an oral dose of 25 mg/kg. Rat and dog studies showed that 17 has good pharmacokinetic properties, with oral bioavailabilities of 55.7 and 54.0%, respectively, and shows excellent safety profiles even at a high dose of 200 mg/kg in these animals. Based on these results, 17 is currently being evaluated in a phase I clinical trial for anemia.


    Xiaojin Zhang, Yonghua Lei, Tianhan Hu, Yue Wu, Zhihong Li, Zhensheng Jiang, Changyong Yang, Lianshan Zhang, Qidong You. Discovery of Clinical Candidate (5-(3-(4-Chlorophenoxy)prop-1-yn-1-yl)-3-hydroxypicolinoyl)glycine, an Orally Bioavailable Prolyl Hydroxylase Inhibitor for the Treatment of Anemia. Journal of medicinal chemistry. 2020 Sep 10;63(17):10045-10060

    Expand section icon Mesh Tags

    Expand section icon Substances

    PMID: 32787144

    View Full Text